Here's what to look out for at the American Academy of Ophthalmology's annual meeting later this week.
News & Analysis: Adverum Biotechnologies, Inc.
Even on an up day for the stock market, these companies lost a lot of ground.
The biotech’s gene therapy isn’t helping patients see better.
ADVM earnings call for the period ending June 30, 2019.
Adverum Biotechnologies and Catalyst Pharmaceuticals could both post sizable gains next month.
Two growth stocks putting up great results and another that's out of favor but still delivering -- here's a trio you need to look at right now.
These biotech stocks have at least quadrupled in just over six months this year.
Good news has a way of attracting suitors.
Can these high-flying biotech stocks keep the momentum going?
The gene therapy developer has dropped its most advanced clinical trial.